Somewhere between a pharmacy queue and a group chat, weight loss became a product with a price list. The Ozempic economy is not only a market for medication—it is a change in the air around bodies, appetite, and what counts as effort. This article is about living inside that atmosphere with your self-respect intact, whatever you decide about treatment.
What the “Ozempic economy” actually means
The scale is easiest to see in money. Analysts at PEX estimate that spending on GLP-1 medications in Poland reached roughly PLN 3.4 billion in 2025, up from PLN 1.8 billion in 2024 and PLN 0.6 billion in 2022, with about PLN 2.8 billion of the 2025 total falling outside public reimbursement[1].
“Ozempic” has become shorthand, though, and shorthand flattens things. That total covers several different medicines and several different reasons for taking them, type 2 diabetes among them[1]. “Outside reimbursement” describes how a prescription was paid for rather than why it was written, and the distinction matters for a second reason: when access depends heavily on private spending, differences in income are easily misread as differences in discipline.
Numbers like that describe a market, but they also describe a mood. Researchers in the field of body image argue that while the biomedical effects of these drugs are being studied intensively, their psychological and cultural consequences remain comparatively underexamined—including how they reshape public conversation about bodies, health, and personal responsibility[2].
That is the part you live in. You do not need a prescription to feel the shift, because the shift is in how people talk.
A new kind of social pressure
Appearance pressure is not new. What is new is the implication that a body is now a solvable problem with a known cost, which quietly reframes staying the same as a choice you keep making.
Early research hints at who feels that pull most. In a study of 225 undergraduates at one U.S. university, students who reported the strongest interest in trying GLP-1s—and the greatest willingness to tolerate side effects—also reported more body shame, more body surveillance, more weight concern, and lower body appreciation[3]. It is worth saying plainly what tolerating them means: in a manufacturer-funded trial of once-weekly semaglutide in adults with overweight or obesity and without diabetes, nausea and diarrhea were the most common adverse events, usually transient and mild to moderate, and gastrointestinal events led 4.5% of those taking semaglutide to stop treatment[4].
Read that first finding carefully, because it is easy to over-read. The study was cross-sectional and conducted with a small, young, mostly female sample, so it cannot tell us what causes what, and it says nothing about people taking these medications under medical supervision for a diagnosed condition. What it does suggest is that interest in a treatment can travel alongside distress about one’s body—which is worth noticing in yourself, without shame.
There is a second pressure underneath the first, and it pulls the other way. Many readers spent the past decade learning that a body is not a project, and that acceptance is possible without changing anything. An effective medication has not erased that lesson; it has set it against a culture that returned to admiring thinness almost immediately. The result is a double bind—you can feel you have failed for not losing weight and, at the same time, feel you have failed your own principles for considering the option. Both feelings can be present at once, and neither one settles what you should do.
When everyone else seems to be shrinking
Body dissatisfaction is rarely manufactured by a mirror alone. Comparison does much of the work, and the Ozempic economy has handed it fresh material: before-and-after posts, speculation about who is using what, and the sense that everyone else has found an option you have not.
A meta-analysis pooling 83 studies and 55,440 participants found a moderate association between higher online social comparison and greater body image concerns, and a similar pattern for eating disorder symptoms[5]. An earlier meta-analytic review reached a comparable conclusion for comparison more generally, with larger effects observed among women[6]. Both bodies of work are largely correlational, so they describe a consistent relationship rather than proof that comparison alone drives distress.
Still, something practical follows. Exposure is easier to change than the reflex it triggers, and muting a keyword, unfollowing an account, or leaving a group chat takes less effort than trying not to compare once an image is already in front of you.
Weight stigma may not disappear when weight does
One assumption underneath the whole conversation is that a smaller body will quiet the inner critic. The evidence is less comforting. A systematic review of 74 studies found that weight bias internalization—applying negative weight stereotypes to yourself—was associated with poorer psychological and physical health outcomes, including depressive symptoms, body image disturbance, and disordered eating[7].
Internalized judgment is a learned relationship with yourself, and there is no guarantee it resolves when the number on a scale changes. Body image researchers make a related point about GLP-1s specifically: the aim should be that expanding use sits alongside psychological support, rather than reinforcing self-worth that depends on appearance[2]. This is one reason the pressure of this moment deserves attention regardless of what you weigh, and regardless of whether medication is part of your life.
Appetite as information, not an enemy
The cultural story treats hunger as a personal failing—something a better-disciplined person would not feel. Two different things are worth separating here. Appetite regulation is physiological and can be genuinely dysregulated; nothing below implies it sits under voluntary control, and a medicine that changes appetite signaling is acting on biology, not on character. What is worth questioning is the moral story laid over the sensation. Physical hunger and the urge to eat are also not always the same experience—the second can follow poor sleep, cold, illness, boredom, or grief—and treating either as a failure of willpower discards useful information along with the discomfort.
Attention is how you receive that information. A meta-analysis of 97 studies found that intuitive eating—broadly, eating in response to internal hunger and fullness cues rather than external rules—was positively associated with positive body image, self-esteem, and wellbeing, and negatively associated with eating disorder symptoms[8]. The caveats matter: roughly 89% of those studies were cross-sectional, so the direction of the relationship is unclear, and intuitive eating is not framed in this literature as a weight-loss method. What that work documents are psychological correlates rather than proven benefits, and the suggestions below follow from the idea rather than from the studies.
- Separate the signal from the verdict: “I am hungry” is information. “I am hungry, which means I am weak” is a judgment you have added.
- Ask what kind of hunger it is: Physical emptiness, a craving for a specific taste, and the pull toward comfort after a hard day are different experiences with different useful responses.
- Eat one meal a day without a screen: Not every meal. One is enough to notice how different it feels.
- Drop the moral vocabulary: Food is not “clean,” “sinful,” or “earned.” Those words import a verdict before you have tasted anything.
None of this is a weight-loss technique, and it is not offered as an alternative to medical treatment. Our guide to mindful eating covers these practices in more depth, and the broader pattern of turning wellness into a performance is explored in our piece on the culture of hyperoptimization.
An important caution: if you are living with an eating disorder or in recovery, structured attention to hunger, fullness, or food rules can be harmful rather than helpful. If these practices increase anxiety or compulsive checking, or conflict with a treatment plan, stop and speak with the clinician managing your care.
When treatment and body image coexist
Nothing above is an argument against medication, and it is worth being explicit about that, because articles like this one often imply otherwise by omission. Choosing treatment and valuing your body are not opposing positions. People arrive at a prescription for many reasons, and a decision made inside a loud culture is still your decision to make.
Researchers expect psychological responses to vary widely from person to person, and the evidence base is not yet strong enough to predict who will feel what[2]. Some people describe relief, more physical comfort, or a quieter relationship with food. Others describe ambivalence, unwanted attention, or the strange experience of being treated better and liking that fact less than they expected. Some notice no particular change in how they feel about their body at all.
None of those reactions is evidence that you decided wrongly. Feeling good about a change does not make you shallow, and finding it difficult does not make you ungrateful. If the psychological side of treatment is hard, that is a reason to seek support, not a reason for silence.
What medication does not replace
GLP-1 receptor agonists are prescription medicines with genuine clinical uses, real side effects, and specific indications. Whether one is appropriate for you is a decision for you and your doctor, and nothing here is an argument for or against taking one.
It is worth knowing what the trial evidence shows about stopping, though. In an exploratory extension of the STEP 1 trial that followed 327 participants for a further year, those who had been taking semaglutide and then stopped it along with the accompanying lifestyle program regained, on average, about two-thirds of the weight they had lost, and most cardiometabolic improvements moved back toward baseline[9].
The trial’s authors read this as suggesting that continued treatment may be needed to maintain the improvement achieved with semaglutide in that population. It is a finding about how long one drug’s effect lasts; it says nothing about willpower, and the extension did not measure stress, comfort, comparison, or self-talk, so it supports no conclusion about them. Which is rather the point—those parts of eating sit outside what the trial measured and outside what a prescription is designed to do, so they stay worth tending whatever you decide. Journaling can help you notice such patterns without turning them into another metric; our guide to journaling for stress relief offers a starting point.
Talking about it without judgment
The Ozempic economy has made bodies a topic again, often clumsily. A few habits help—both when you are the one talking and when you are the one being talked about.
- Avoid unsolicited comments about weight change: Including admiring ones. You rarely know the cause, and the person may not want their body made into a topic.
- Do not speculate about who is using what: Medical treatment is private, and speculation is a form of surveillance.
- Resist the moral frame in both directions: Taking medication is not cheating, and declining it is not virtue.
- Ask before advising: “Do you want thoughts, or would you rather I just listen?” is almost always the better opening.
- Set a boundary without explaining it: “I would rather not discuss my weight or my medication” is a complete sentence. You do not owe anyone a medical disclosure.
If someone confides that they are using or considering a GLP-1, the most useful response is usually curiosity about how they are doing, not an assessment of their decision.
When to seek support
Speak with a qualified clinician if food, weight, or body image occupy your thoughts in a way that interferes with daily life, if you are restricting, purging, or bingeing, or if low mood or anxiety has become persistent. If you are considering or currently taking a GLP-1 medication, a doctor who knows your full history—including any history of disordered eating—is the right person to help you weigh that decision. Our mental wellbeing guide outlines what support can look like.
You are allowed to opt out of the referendum on your own body. Start with one small thing: eat one meal this week without a screen, or mute one account that turns bodies into before-and-after photographs. The culture will keep changing its mind about bodies. Your relationship with your own does not have to follow it.
References
- Brzózka M. “Poland’s new obsession with medical weight loss.” XYZ, 2026. Market figures attributed to the analytics firm PEX. https://xyz.pl/poland-unpacked/polands-new-obsession-with-medical-weight-loss-8930/.
- Craddock N, Schneider J. “Body image in the age of GLP-1s: Emerging questions for research and practice.” Body Image, 2026. https://doi.org/10.1016/j.bodyim.2026.102095.
- Markey CH, August KJ, Malik D, Richeson A. “Body image and interest in GLP-1 weight loss medications.” Body Image, 2025. https://doi.org/10.1016/j.bodyim.2025.101890.
- Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021. Funded by Novo Nordisk. https://doi.org/10.1056/NEJMoa2032183.
- Bonfanti RC, Melchiori F, Teti A, et al. “The association between social comparison in social media, body image concerns and eating disorder symptoms: A systematic review and meta-analysis.” Body Image, 2025. https://doi.org/10.1016/j.bodyim.2024.101841.
- Myers TA, Crowther JH. “Social comparison as a predictor of body dissatisfaction: A meta-analytic review.” Journal of Abnormal Psychology, 2009. https://doi.org/10.1037/a0016763.
- Pearl RL, Puhl RM. “Weight bias internalization and health: a systematic review.” Obesity Reviews, 2018. https://doi.org/10.1111/obr.12701.
- Linardon J, Tylka TL, Fuller-Tyszkiewicz M. “Intuitive eating and its psychological correlates: A meta-analysis.” International Journal of Eating Disorders, 2021. https://doi.org/10.1002/eat.23509.
- Wilding JPH, Batterham RL, Davies M, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.” Diabetes, Obesity and Metabolism, 2022. https://doi.org/10.1111/dom.14725.
Frequently Asked Questions
Does losing weight improve body image?
Not reliably. Research on weight bias internalization suggests that self-directed judgment is a learned relationship with yourself, and it does not necessarily resolve when body size changes.
Why do I feel more pressure about my weight now?
Widely available weight-loss medication can make body size feel like a solvable problem with a known price, which reframes staying the same as a repeated choice. Social comparison online tends to amplify that effect.
Is mindful eating an alternative to GLP-1 medication?
No. Intuitive and mindful eating are not framed in the research as weight-loss methods, and their documented benefits are psychological. They are a complement to medical care, not a replacement for it.
What happens if you stop taking semaglutide?
In the STEP 1 trial extension, participants regained about two-thirds of the weight they had lost within a year of stopping treatment, and cardiometabolic improvements largely reverted. Any change to treatment should be discussed with your doctor.